Loading...

NeuBase Therapeutics, Inc.

NBSE•NASDAQ
HealthcareBiotechnology
$0.38
$-0.01(-1.56%)

NeuBase Therapeutics, Inc. (NBSE) Stock Overview

Explore NeuBase Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Stats data is not available for NBSEStats details for NBSE are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for NBSEAnalyst Recommendations details for NBSE are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1; NT0300, a PATrOL-enabled therapeutic treatment to target the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.

CEO

Mr. Todd P. Branning

Employees

37

Headquarters

350 Technology Drive, Pittsburgh, PA

Founded

2004

Frequently Asked Questions